Clearmind Medicine logo

Clearmind Medicine

CMND | NASDAQ
Chart Builder DCF Calculator
$4.18
-$0.35 (-7.73%)
At close: Nov 16, 2026, 4:00 PM ET
$4.00
-$0.18 (-4.31%)
After-hours: Nov 16, 2026, 7:30 PM ET
-7.73%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
28.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #838/1021 (Top 82%)

Key Statistics

Market Data

Market Cap $2.12M
1D Range
4.00 4.27
52W Range
4.00 886.40

Valuation (TTM)

PE -0.05
PB 0.16
EV/EBITDA N/A

Valuation (NTM)

Forward PE N/A
Forward PEG 0.00
Price Target $0.00
Loading financial charts...

Profile

Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental ...

Sector Healthcare
Industry Biotechnology
Employees 4
IPO Date Nov 15, 2022
Fiscal Year November - October

Latest News

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

1 month ago · globenewswire.com

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA

1 month ago · globenewswire.com

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

2 months ago · thenewswire.com

NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations

2 months ago · globenewswire.com

Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations
Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio

2 months ago · thenewswire.com

Stickit Technologies Announces Corporate Update: Leadership Appointments, Capital Restructuring & Loan Acquisition, And Update Of Intellectual Property Portfolio
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.

2 months ago · globenewswire.com

Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

2 months ago · globenewswire.com

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results

2 months ago · globenewswire.com

Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results
Clearmind Medicine Stock Slides Friday: What's Happening?

2 months ago · benzinga.com

Clearmind Medicine Stock Slides Friday: What's Happening?
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis

2 months ago · globenewswire.com

Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.